Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Today’s Forbes Daily newsletter covers Amazon’s latest AI investment, Novo Nordisk’s tough Ozempic test, SoftBank stumbles, ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo misses in Alzheimer's trial; Insurer shares rise on report Trump will unveil health policy proposal; Bayer’s stroke drug succeeds in late-stage trial.

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

U.S. stock futures were flat early in European business hours Tuesday and international equities were mixed amid further signs of returning calm after last week's volatility. Broad gains in tech ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?